CSTL Stock: Price, Earnings History and SEC Filings
Castle Biosciences, Inc. (CSTL) last traded at $37.16, down 3.51% on the latest session and up 4.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.07 against an analyst estimate of $-0.44, a beat of 84.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CSTL earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $-0.07 | $-0.44 | +84.09% |
| Mar 2026 | May 6, 2026 | $-0.49 | $-0.56 | +12.50% |
| Dec 2025 | Feb 26, 2026 | $-0.08 | $-0.23 | +65.22% |
| Sep 2025 | Nov 3, 2025 | $-0.02 | $-0.34 | +94.12% |
CSTL beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How CSTL reacts to earnings
Across its last 8 earnings releases, CSTL moved 14.3% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-30 | After close | +4.52% |
| 2026-05-06 | After close | -22.26% |
| 2026-02-26 | After close | -7.25% |
| 2026-01-13 | Before open | -0.05% |
| 2025-11-03 | After close | +21.70% |
| 2025-08-04 | After close | +32.83% |
| 2025-05-05 | After close | -11.36% |
| 2025-02-27 | After close | -14.24% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
CSTL financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $344M | -$24M | $28M | -7.0% | $-0.83 |
| 2024 | $332M | $18M | $37M | 5.5% | $0.62 |
| 2023 | $220M | -$57M | -$19M | -26.1% | $-2.14 |
| 2022 | $137M | -$67M | -$47M | -49.0% | $-2.58 |
| 2021 | $94M | -$31M | -$22M | -33.3% | $-1.24 |
| 2020 | $63M | -$10M | $5M | -16.4% | $-0.54 |
| 2019 | $52M | $5M | $6M | 10.2% | $-0.21 |
| 2018 | $23M | -$6M | -$13M | -27.9% | $-5.33 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for CSTL
- 10-Q · Jul 30, 2026
- 8-K · Jul 30, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · May 29, 2026Shareholder vote
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- DEF 14A · Apr 8, 2026
- 10-K · Feb 26, 2026
- 8-K · Feb 26, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jan 13, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Nov 3, 2025
Insider filing activity
CSTL insiders filed 21 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
CSTL news
- Castle Biosciences to Participate in Upcoming Investor ConferencesOct 28, 2026 · finance.yahoo.com
About Castle Biosciences, Inc.
Castle Biosciences, Inc. (CSTL) is a US-listed public company on Nasdaq. The SEC classifies its business as Services-medical Laboratories. It is incorporated in DE. Its fiscal year ends in December.